Business Context and Reporting Period
Company: AnaptysBio, Inc. (ANAB)
Filing Type: Form 8-K (Current Report)
Date of Report: May 18, 2026
Event: The Board of Directors approved a change in the Company's fiscal year-end from December 31 to June 30.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses solely on a corporate governance change regarding the fiscal calendar.
Material Changes
- Fiscal Year Change: The fiscal year-end is shifting from December 31 to June 30.
- Transition Period: A six-month transition period is established from January 1, 2026, through June 30, 2026.
- Reporting Schedule: The Company will file a transition report on Form 10-KT for the period ending June 30, 2026. Quarterly reports under the new fiscal year will commence with the quarter ending September 30, 2026.
Guidance, Outlook, and Risks
The filing contains no financial guidance, management commentary on operational outlook, specific risk factors, or contingencies beyond the administrative change to the fiscal calendar.
Key Facts for Investors to Verify
- Confirmation of the upcoming Form 10-KT filing for the transition period (January 1, 2026 – June 30, 2026).
- Impact of the fiscal year change on future quarterly earnings release dates.
- Any potential tax or accounting implications of the fiscal year shift not detailed in this 8-K.